Halozyme Therapeutics, Inc.
(NASDAQ : HALO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. 1.25%67.841.0%$996.23m
BIIBBiogen, Inc. 0.15%337.151.5%$676.13m
AMGNAmgen, Inc. 0.14%222.441.3%$549.13m
ILMNIllumina, Inc. -0.67%298.443.5%$419.18m
REGNRegeneron Pharmaceuticals, Inc. -0.55%396.952.6%$352.45m
VRTXVertex Pharmaceuticals, Inc. -0.05%244.991.9%$341.98m
ALXNAlexion Pharmaceuticals, Inc. 0.13%102.672.0%$217.58m
AAgilent Technologies, Inc. -0.73%83.731.6%$162.08m
EXASEXACT Sciences Corp. -2.55%100.0224.0%$160.61m
SGENSeattle Genetics, Inc. 0.10%118.456.1%$114.87m
INCYIncyte Corp. -0.65%82.242.5%$113.52m
MRNAModerna, Inc. -1.94%18.180.0%$104.70m
XLRNAcceleron Pharma, Inc. -0.17%94.696.1%$94.00m
ALNYAlnylam Pharmaceuticals, Inc. -2.14%130.278.7%$92.41m
BMRNBioMarin Pharmaceutical, Inc. 3.29%92.614.3%$91.80m

Company Profile

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.